WVE
What one share of Wave Life Sciences holds
Pharmaceutical Preparations
We are a clinical-stage biotechnology company focused on unlocking the broad potential of ribonucleic acid (“RNA”) medicines (also known as oligonucleotides), or those targeting RNA, to transform human health. Our RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and common disorders.
Wave Life Sciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.35 |
|---|---|
| Profit | −$1.08 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$1.03 |
| Cash and investments | $1.90 |
| Book value | $2.35 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2013 | — | −$1.90 | $0.03 | −$2.06 | — | −$4.45 |
| 2014 | — | −$1.34 | $0.15 | −$1.28 | — | $0.48 |
| 2015 | $0.01 | −$1.83 | $0.18 | −$1.37 | — | — |
| 2016 | $0.07 | −$2.44 | $0.24 | −$1.64 | — | $5.73 |
| 2017 | $0.14 | −$3.85 | $0.71 | −$3.87 | — | $5.02 |
| 2018 | $0.50 | −$5.06 | $0.34 | −$1.13 | — | $2.49 |
| 2019 | $0.47 | −$5.72 | $0.12 | −$5.67 | — | $1.86 |
| 2020 | $0.51 | −$3.82 | $0.03 | −$2.99 | — | $1.70 |
| 2021 | $0.79 | −$2.36 | $0.01 | −$1.73 | — | $0.54 |
| 2022 | $0.05 | −$2.05 | $0.02 | −$1.64 | — | −$0.52 |
| 2023 | $1.07 | −$0.54 | $0.01 | −$0.19 | — | $0.33 |
| 2024 | $0.78 | −$0.70 | $0.01 | −$1.10 | — | $1.37 |
| 2025 | $0.25 | −$1.21 | $0.00 | −$1.12 | — | $2.76 |